Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2, Multicenter, Open-Label, Two-Stage Study to Evaluate the Safety and Efficacy of Intra-Arterial Catheter-Directed Alfimeprase for Restoration of Neurologic Function and Rapid Opening of Arteries in Stroke (CARNEROS-1).

Next Previous
X
Search
Trial Profile

Phase 2, Multicenter, Open-Label, Two-Stage Study to Evaluate the Safety and Efficacy of Intra-Arterial Catheter-Directed Alfimeprase for Restoration of Neurologic Function and Rapid Opening of Arteries in Stroke (CARNEROS-1).

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alfimeprase (Primary)
  • Indications Embolism and thrombosis; Stroke
  • Focus Proof of concept; Therapeutic Use
  • Acronyms CARNEROS-1
  • Sponsors Nuvelo

    • Most Recent Events

    • 05 May 2009 Sponsor, affiliate and lead trial centre (ARCA Biopharma) added as reported by ClinicalTrials.gov.
    • 17 Mar 2008 Status changed from recruiting to discontinued: Nuvelo have decided to terminate their clinical development of alfimeprase after obtaining disappointing efficacy results in the SONOMA-3 trial [see media release 9086453 and profile 700018108].
    • 12 Dec 2007 First patient dosed according to Nuvelo media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top